Sarepta Therapeutics (SRPT) says siRNA achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1
Importance
Level 1
#SAREPTA THERAPEUTICS INC#SRPT.US#EU SESSION#US SESSION#US EQUITIES
© 2026 Newsquawk. All rights reserved.